Drug Trial Radar · NCT06407934
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,541
Actual
Start
May 8, 2024
Primary completion
Jun 10, 2026
Study completion Mar 17, 2027
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- May 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 years and older diagnosed with moderate-to-severe atopic dermatitis (AD). The primary objective of ESTUARY is to assess the maintenance of treatment response on continued Q12W dosing compared to treatment withdrawal. Study details include: The study duration will be up to 68 weeks including a 52-week randomized double-blind period, and a 16-week safety follow-up for participants not entering the LTS17367 (RIVER-AD). The study duration will be up to 52 weeks for participants entering the LTS17367 \[RIVER-AD\] study at the Week 52 visit of EFC17600 (ESTUARY).
Conditions
- Dermatitis Atopic
Interventions
AmlitelimabDrug
Pharmaceutical form: Injection solution Route of administration: Subcutaneous (SC) injection
PlaceboDrug
Pharmaceutical form: Injection solution Route of administration: SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- US and US reference countries: Proportion of participants who are responders AND maintained vIGA-AD ≤2 without experiencing relapse among participants who were responders at baseline of ESTUARYTime frame: Week 24
- EU, EU Reference Countries, and Japan: Proportion of participants who maintain treatment response in ESTUARY without experiencing relapseTime frame: Week 48
Locations
324 sites in 27 countries. Site status is shown where the registry gives one.
Cahaba Dermatology & Skin Health Center- Site Number : 8401066
Birmingham, Alabama
Center for Dermatology and Plastic Surgery- Site Number : 8401119
Scottsdale, Arizona
Scottsdale Clinical Trials- Site Number : 8401149
Scottsdale, Arizona
Eclipse Clinical Research- Site Number : 8401158
Tucson, Arizona
Johnson Dermatology- Site Number : 8401076
Fort Smith, Arkansas
Encino Research Center- Site Number : 8401042
Encino, California
First OC Dermatology- Site Number : 8401025
Fountain Valley, California
Center for Dermatology Clinical Research- Site Number : 8401018
Fremont, California
Marvel Clinical Research- Site Number : 8401102
Huntington Beach, California
Sunwise Clinical Research- Site Number : 8401022
Lafayette, California
Torrance Clinical Research - Narbonne Avenue- Site Number : 8401027
Lomita, California
Dermatology Research Associates - Los Angeles- Site Number : 8401092
Los Angeles, California
LA Universal Research Center- Site Number : 8401064
Los Angeles, California
Northridge Clinical Trials - Northridge- Site Number : 8401080
Northridge, California
Cura Clinical Research - Oxnard- Site Number : 8401142
Oxnard, California
Southern California Dermatology- Site Number : 8401043
Santa Ana, California
Clinical Science Institute- Site Number : 8401028
Santa Monica, California
UConn Health - Farmington- Site Number : 8401115
Farmington, Connecticut
Pediatric Skin Research- Site Number : 8401198
Coral Gables, Florida
St. Jude Clinical Research- Site Number : 8401287
Doral, Florida
Beth Israel Deaconess Medical Center - Fort Myers- Site Number : 8401286
Fort Myers, Florida
Direct Helpers Research Center- Site Number : 8401056
Hialeah, Florida
Encore Medical Research - Hollywood- Site Number : 8401030
Hollywood, Florida
Clever Medical Research- Site Number : 8401160
Miami, Florida
Acevedo Clinical Research Associates- Site Number : 8401088
Miami, Florida
Florida International Research Center- Site Number : 8401091
Miami, Florida
Miami Dermatology and Laser Research - Miami - Southwest 87th Avenue- Site Number : 8401086
Miami, Florida
Anchor Medical Research- Site Number : 8401300
Miami, Florida
Savin Medical Group - Miami Lakes- Site Number : 8401085
Miami Lakes, Florida
Nuline Clinical Trial Center- Site Number : 8401161
Pompano Beach, Florida
Global Clinical Professionals (GCP)- Site Number : 8401045
St. Petersburg, Florida
Clinical Research Trials of Florida- Site Number : 8401023
Tampa, Florida
AllerVie Clinical Research - Columbus- Site Number : 8401104
Columbus, Georgia
Cleaver Medical Group- Site Number : 8401138
Dawsonville, Georgia
First Georgia Physician Group- Site Number : 8401190
Fayetteville, Georgia
Skin Care Physicians of Georgia - Macon- Site Number : 8401034
Macon, Georgia
Javara Research - Thomasville- Site Number : 8401189
Thomasville, Georgia
Rophe Adult & Pediatric Medicine- Site Number : 8401289
Union City, Georgia
NorthShore University Health System - Endeavor Health Medical Group - Skokie - Woods Drive- Site Number : 8401038
Skokie, Illinois
Dawes Fretzin Clinical Research- Site Number : 8401015
Indianapolis, Indiana
Showing 40 of 324 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.